We report a case of bioresorbable vascular scaffold restenosis which could be caused by abnormal resorption 17months after implantation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.carrev.2016.05.013 | DOI Listing |
J Mech Behav Biomed Mater
December 2024
Department of Bionanosystem Engineering, Graduate School, Jeonbuk National University, Jeonju 54896, Republic of Korea; Department of Bionanotechnology and Bioconvergence Engineering, Graduate School, Jeonbuk National University, Jeonju 54896, Republic of Korea; Department of Mechanical Design Engineering, Graduate School, Jeonbuk National University, Jeonju 54896, Republic of Korea; Advanced Mechanical Components Design & Research Center, Jeonbuk National University, Jeonju 54896, Republic of Korea; Innovative Mechanobio Active Materials Based Medical Device Demonstration Center, Jeonbuk National University, Jeonju 54896, Republic of Korea. Electronic address:
JACC Cardiovasc Interv
November 2024
Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland; Faculty of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland; University of Bern, Bern, Switzerland. Electronic address:
Background: Abbreviated antiplatelet therapy (APT) reduces bleeding without increasing ischemic events in largely unselected high bleeding risk (HBR) patients undergoing percutaneous coronary intervention (PCI). Diabetes mellitus (DM) is associated with higher ischemic risk, and its impact on the safety and effectiveness of abbreviated APT in HBR PCI patients remains unknown.
Objectives: This study sought to investigate the comparative effectiveness of abbreviated (1 month) vs standard (≥3 months) APT in HBR patients with and without DM after biodegradable polymer sirolimus-eluting coronary stent implantation.
J Neurointerv Surg
November 2024
Neurosurgery, Kyoto University Graduate School of Medicine Faculty of Medicine, Kyoto, Japan.
Acta Biomater
November 2024
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Crystal structure and morphology dictate the mechanical, thermal, and degradation properties of poly l-lactide (PLLA), the structural polymer of the first clinically approved bioresorbable vascular scaffolds (BVS). New experimental methods are developed to reveal the underlying mechanisms governing structure formation during the crimping step of the BVS manufacturing process. Our research specifically examines the "U-bends" - the region where the curvature is highest and stress is maximised during crimping, which can potentially lead to failure of the device with dramatic consequences on patient life.
View Article and Find Full Text PDFCardiovasc Revasc Med
November 2024
U.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy. Electronic address:
Background: Data on Absorb bioresorbable vascular scaffold (BVS) use in patients presenting with ST-segment elevation myocardial infarction (STEMI) are limited. Furthermore, Absorb studies including STEMI patients lacked a prespecified implantation technique to optimize BVS deployment. This study examines the 5-year outcomes of BVS in STEMI patients using an optimized implantation strategy and the impact of prolonged dual antiplatelet therapy (DAPT).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!